Gapping up
In reaction to strong earnings/guidance:
- N/A.
M&A news:
- SIR +17.1% (Select Income REIT & Government Properties Income Trust (GOV) announce merger)
Other news:
- NEPT +20.4% (received a Confirmation of Readiness letter from Health Canada in regard to its application to become a Licensed Producer under the ACMPR)
- ARGX +12.5% (announces positive topline results from its Phase 2 proof-of-concept clinical trial of efgartigimod in adult primary immune thrombocytopenia patients)
- TEVA +8.4% (receives FDA approval for AJOVY)
- MRSN +4.7% (announces that the FDA has lifted the partial clinical hold on the Phase 1 study of XMT-1522) GLW +2.1% (continued strength)
Analyst comments:
- BBBY +3.5% (upgraded to Mkt Perform from Underperform at Raymond James)
- MBUU +2.3% (upgraded to Buy from Neutral at B. Riley FBR)
- A +1% (added to Conviction Buy List at Goldman)
- MA +0.9% (added to Conviction Buy List at Goldman)
- AVGO +0.9% (upgraded to Buy from Neutral at Nomura)
- AXP +0.9% (upgraded to Overweight from Equal-Weight at Stephens)
- PXD +0.7% (upgraded to Positive from Neutral at Susquehanna)